Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.772
Peer-review started: April 6, 2018
First decision: May 16, 2018
Revised: June 14, 2018
Accepted: June 27, 2018
Article in press: June 28, 2018
Published online: October 27, 2018
Processing time: 205 Days and 15.8 Hours
In a routine abdominal sonography of a 63-year-old asymptomatic male, a large central tumor in the liver was detected.
According to the abdominal sonography, the magnetic resonance imaging and the pathologically increased tumor marker alpha-fetoprotein and liver function panel, a hepatic malignancy was urgently suspected.
Liver cirrhosis, cholangiocellular carcinoma, liver angiosarcoma, liver metastases of non-hepatic origin.
The laboratory tests showed significant increase of the tumor marker alpha-fetoprotein and the cholestatic parameters gamma-glutamyltransferase and alkaline phosphatase.
Magnetic resonance imaging and computed tomography of the abdomen revealed the main tumor mass to be of about 13.4 cm × 7.1 cm in size, encompassing segments I, IV, V and VIII, as well as satellite metastases in segments II and III. The tumor involved all three hepatic veins and the portal vein, compressing the inferior vena cava.
A liver biopsy confirmed a diagnosis of hepatocellular carcinoma (HCC), Edmondson-Steiner-grade II, with partially cirrhotic parenchymal modification.
The patient was treated with proton beam therapy (PBT) in apneic oxygenation at the Rinecker Proton Therapy Center, at a total dose of 60 Gy (relative biological effectiveness) in 20 fractions.
We use the apneic oxygenation to manage respiratory motion of the tumor and to reduce the safety margin, which enables the sparing of uninvolved liver parenchyma and other surrounding organs at risk as well as a dose escalation.
The patient is free of tumor recurrence in a period of 4 years after the treatment. PBT is a safe and effective therapy for large unresectable HCC with vascular invasion and intrahepatic metastases.